Amneal Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Amneal Pharmaceuticals has been growing earnings at an average annual rate of 19.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 7.3% per year.

Key information

19.3%

Earnings growth rate

23.9%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	7.3%
Return on equity	-79.5%
Net Margin	-3.5%
Next Earnings Update	03 May 2024

Recent past performance updates

Recent updates

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Aug 04

Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of Debt

Apr 16

Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old Management

Mar 30

Revisiting Amneal Pharmaceuticals After Its CEO Buys Shares

Dec 22

Revenue & Expenses Breakdown
Beta

How Amneal Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:AMRX Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	2,394	-84	430	164
30 Sep 23	2,386	10	423	160
30 Jun 23	2,312	-2	410	169
31 Mar 23	2,272	-135	403	182
31 Dec 22	2,212	-130	400	196
30 Sep 22	2,139	-132	395	206
30 Jun 22	2,122	-134	386	204
31 Mar 22	2,098	2	373	206
31 Dec 21	2,094	11	366	202
30 Sep 21	2,067	14	353	203
30 Jun 21	2,058	9	345	199
31 Mar 21	1,987	-17	339	192
31 Dec 20	1,993	91	327	180
30 Sep 20	1,880	62	316	175
30 Jun 20	1,739	-194	297	168
31 Mar 20	1,679	-199	283	171
31 Dec 19	1,626	-362	290	188
30 Sep 19	1,727	-339	287	197
30 Jun 19	1,825	-67	298	202
31 Mar 19	1,834	-69	287	204
31 Dec 18	1,663	-21	228	194
30 Sep 18	1,459	155	184	180
30 Jun 18	1,237	149	136	179
31 Mar 18	1,083	168	106	176
31 Dec 17	1,034	168	109	171
30 Sep 17	1,039	54	113	171
31 Dec 16	1,018	207	119	179
31 Dec 15	866	169	110	137
31 Dec 14	786	177	85	107

Quality Earnings: AMRX is currently unprofitable.

Growing Profit Margin: AMRX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AMRX is unprofitable, but has reduced losses over the past 5 years at a rate of 19.3% per year.

Accelerating Growth: Unable to compare AMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).

Return on Equity

High ROE: AMRX has a negative Return on Equity (-79.48%), as it is currently unprofitable.

Amneal Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Full year 2023 earnings: EPS misses analyst expectations

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Recent updates

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Price target increased by 7.3% to US$7.31

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Insider exercised options and sold US$332k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

New major risk - Financial position

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Price target increased by 50% to US$5.25

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals Could Have An Upbeat Q2

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Consensus EPS estimates fall by 25%

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

Price target decreased by 18% to US$3.50

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Price target decreased by 18% to US$4.20

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Amneal Pharmaceuticals: Risk Still Persists

Amneal Pharma reaffirms 2022 guidance

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Price target decreased to US$5.10

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Consensus forecasts updated

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Price target decreased to US$5.80

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Revenue & Expenses Breakdown
Beta